References
- Strohl W. Current progress in innovative engineered antibodies. Protein & Cell. 2018;9(1):86–13. doi:https://doi.org/10.1007/s13238-017-0457-8.
- Kaplon H, Reichert JM. Antibodies to watch in 2019. MABS. 2019;11(2):219–38. doi:https://doi.org/10.1080/19420862.2018.1556465.
- Dodd RB, Wilkinson T, Schofield DJ. Therapeutic monoclonal antibodies to complex membrane protein targets: antigen generation and antibody discovery strategies. BioDrugs. 2018;32(4):339–55. doi:https://doi.org/10.1007/s40259-018-0289-y.
- Heukers R, De Groof TWM, Smit MJ. Nanobodies detecting and modulating GPCRs outside in and inside out. Curr Opin Cell Biol. 2019;57:115–22. doi:https://doi.org/10.1016/j.ceb.2019.01.003.
- Jo E-K. Interplay between host and pathogen: immune defense and beyond. Exp Mol Med. 2019;51(12):1–9. doi:https://doi.org/10.1038/s12276-019-0281-8.
- Hutchings CJ, Koglin M, Olson WC, Marshall FH. Opportunities for therapeutic antibodies directed at G-protein-coupled receptors. Nat Rev Drug Discov. 2017;16(11):787–810. doi:https://doi.org/10.1038/nrd.2017.91.
- Hutchings CJ, Colussia P, Clark TG. Ion channels as therapeutic antibody targets. MABS. 2019;11(2):265–96. doi:https://doi.org/10.1080/19420862.2018.1548232.
- Palczewski K. Crystal structure of rhodopsin: A G protein-coupled receptor. Science. 2000;289(5480):739–45. doi:https://doi.org/10.1126/science.289.5480.739.
- Henderson R, Baldwin JM, Ceska TA, Zemlin F, Beckmann E, Downing KH. Model for the structure of bacteriorhodopsin based on high-resolution electron cryo-microscopy. J Mol Biol. 1990;213(4):899–929. doi:https://doi.org/10.1016/S0022-2836(05)80271-2.
- Rosenbaum DM, Cherezov V, Hanson MA, Rasmussen SG, Thian FS, Kobilka TS, Choi H-J, Yao X-J, Weis WI, Stevens RC, et al. GPCR engineering yields high-resolution structural insights into 2-adrenergic receptor function. Science. 2007;318(5854):1266–73. doi:https://doi.org/10.1126/science.1150609.
- Cherezov V, Rosenbaum DM, Hanson MA, Rasmussen SG, Thian FS, Kobilka TS, Choi H-J, Kuhn P, Weis WI, Kobilka BK, et al. High-resolution crystal structure of an engineered human 2-adrenergic g protein-coupled receptor. Science. 2007;318(5854):1258–65. doi:https://doi.org/10.1126/science.1150577.
- Lantez V, Nikolaidis I, Rechenmann M, Vernet T, Noirclerc-Savoye M. Rapid automated detergent screening for the solubilization and purification of membrane proteins and complexes. Eng Life Sci. 2015;15(1):39–50. doi:https://doi.org/10.1002/elsc.201400187.
- Mandon ED, Agez M, Pellegrin R, Igonet S, Jawhari A. Novel systematic detergent screening method for membrane proteins solubilization. Anal Biochem. 2017;517:40–49. doi:https://doi.org/10.1016/j.ab.2016.11.008.
- Tehan BG, Christopher JA. The use of conformationally thermostabilised GPCRs in drug discovery: application to fragment, structure and biophysical techniques. Curr Opin Pharmacol. 2016;30:8–13. doi:https://doi.org/10.1016/j.coph.2016.06.010.
- Soave M, Cseke G, Hutchings CJ, Brown AJH, Woolard J, Hill SJ. A monoclonal antibody raised against a thermo-stabilised β1-adrenoceptor interacts with extracellular loop 2 and acts as a negative allosteric modulator of a sub-set of β1-adrenoceptors expressed in stable cell lines. Biochem Pharmacol. 2018;147:38–54. doi:https://doi.org/10.1016/j.bcp.2017.10.015.
- Sarkar CA, Dodevski I, Kenig M, Dudli S, Mohr A, Hermans E, Pluckthun A. Directed evolution of a G protein-coupled receptor for expression, stability, and binding selectivity. Proc Natl Acad Sci USA. 2008;105(39):14808–13. doi:https://doi.org/10.1073/pnas.0803103105.
- Dodevski I, Pluckthun A. Evolution of three human GPCRs for higher expression and stability. J Mol Biol. 2011;408(4):599–615. doi:https://doi.org/10.1016/j.jmb.2011.02.051.
- Mallipeddi S, Zvonok N, Makriyannis A. Expression, purification and characterization of the human cannabinoid 1 receptor. Sci Rep. 2018;8:2935.
- Mumaw MM, de la Fuente M, Arachiche A, Wahl JK 3rd, Nieman MT. Development and characterization of monoclonal antibodies against protease activated receptor 4 (PAR4). Thromb Res. 2015;135(6):1165–71. doi:https://doi.org/10.1016/j.thromres.2015.03.027.
- Ohta S, Sakaguchi S, Kobayashi Y, Mizuno N, Tago K, Itoh H. Agonistic antibodies reveal the function of GPR56 in human glioma U87-MG cells. Biol Pharm Bull. 2015;38(4):594–600. doi:https://doi.org/10.1248/bpb.b14-00752.
- Shi L, Lehto SG, Zhu DX, Sun H, Zhang J, Smith BP, Immke DC, Wild KD, Xu C. Pharmacologic characterization of AMG 334, a potent and selective human monoclonal antibody against the calcitonin gene-related peptide receptor. J Pharmacol Exp Ther. 2015;356(1):223–31. doi:https://doi.org/10.1124/jpet.115.227793.
- Ishida T, Utsunomiya A, Iida S, Inagaki H, Takatsuka Y, Kusumoto S, Takeuchi G, Shimizu S, Ito M, Komatsu H, et al. Clinical significance of CCR4 expression in adult T-cell leukemia/lymphoma: its close association with skin involvement and unfavorable outcome. Clin Can Res. 2003;9:3625–34.
- Zhang Y, Pool C, Sadler K, Yan H-P, Edl J, Wang X, Boyd JG, Tam JP. Selection of active ScFv to G-protein-coupled receptor CCR5 using surface antigen-mimicking peptides†. Biochemistry. 2004;43(39):12575–84. doi:https://doi.org/10.1021/bi0492152.
- Harris GL, Creason MB, Brulte GB, Herr DR, Agoulnik I. In vitro and in vivo antagonism of a G protein-coupled receptor (S1P3) with a novel blocking monoclonal antibody. PLoS One. 2012;7(4):e35129. doi:https://doi.org/10.1371/journal.pone.0035129.
- Tohidkia MR, Asadi F, Barar J, Omidi Y. Selection of potential therapeutic human single-chain Fv antibodies against cholecystokinin-B/gastrin receptor by phage display technology. BioDrugs. 2013;27(1):55–67. doi:https://doi.org/10.1007/s40259-012-0007-0.
- Boshuizen RS, Marsden C, Turkstra J, Rossant CJ, Slootstra J, Copley C, Schwamborn K. A combination of in vitro techniques for efficient discovery of functional monoclonal antibodies against human CXC chemokine receptor-2 (CXCR2). MABS. 2014;6(6):1415–24. doi:https://doi.org/10.4161/mabs.36237.
- Ho TT, Nguyen JT, Liu J, Stanczak P, Thompson AA, Yan YG, Chen J, Allerston CK, Dillard CL, Xu H, et al. Method for rapid optimization of recombinant GPCR protein expression and stability using virus-like particles. Protein Expr Purif. 2017;133:41–49. doi:https://doi.org/10.1016/j.pep.2017.03.002.
- Denisov IG, Sligar SG. Nanodiscs for structural and functional studies of membrane proteins. Nat Struct Mol Biol. 2016;23(6):481–86. doi:https://doi.org/10.1038/nsmb.3195.
- Lindhoud S, Carvalho V, Pronk JW, Aubin-Tam M-E. SMA-SH: modified Styrene–Maleic acid copolymer for functionalization of lipid nanodiscs. Biomacromolecules. 2016;17(4):1516–22. doi:https://doi.org/10.1021/acs.biomac.6b00140.
- Frauenfeld J, Loving R, Armache J-P, Sonnen AF, Guettou F, Moberg P, Zhu L, Jegerschöld C, Flayhan A, Briggs J, et al. A saposin-lipoprotein nanoparticle system for membrane proteins. Nat Methods. 2016;13(4):345–51. doi:https://doi.org/10.1038/nmeth.3801.
- Rossant CJ, Carroll D, Huang L, Elvin J, Neal F, Walker E, Benschop JJ, Kim EE, Barry ST, Vaughan TJ. Phage display and hybridoma generation of antibodies to human CXCR2 yields antibodies with distinct mechanisms and epitopes. MABS. 2014;6(6):1425–38. doi:https://doi.org/10.4161/mabs.34376.
- Koth CM, Murray JM, Mukund S, Madjidi A, Minn A, Clarke HJ, Wong T, Chiang V, Luis E, Estevez A, et al. Molecular basis for negative regulation of the glucagon receptor. Proc Natl Acad Sci USA. 2012;109(36):14393–98. doi:https://doi.org/10.1073/pnas.1206734109.
- Kuhne MR, Mulvey T, Belanger B, Chen S, Pan C, Chong C, Cao F, Niekro W, Kempe T, Henning KA, et al. BMS-936564/MDX-1338: a fully human anti-CXCR4 antibody induces apoptosis in vitro and shows antitumor activity in vivo in hematologic malignancies. Clin Cancer Res. 2013;19(2):357–66. doi:https://doi.org/10.1158/1078-0432.CCR-12-2333.
- Peyrassol X, Laeremans T, Gouwy M, Lahura V, Debulpaep M, Van Damme J, Steyaert J, Parmentier M, Langer I. Development by genetic immunization of monovalent antibodies (nanobodies) behaving as antagonists of the human ChemR23 receptor. J Immunol. 2016;196(6):2893–901. doi:https://doi.org/10.4049/jimmunol.1500888.
- van der Woning B, De Boeck G, Blanchetot C, Bobkov V, Klarenbeek A, Saunders M, Waelbroeck M, Laeremans T, Steyaert J, Hultberg A, et al. DNA immunization combined with scFv phage display identifies antagonistic GCGR specific antibodies and reveals new epitopes on the small extracellular loops. MABS. 2016;8(6):1126–35. doi:https://doi.org/10.1080/19420862.2016.1189050.
- Saade F, Petrovsky N. Technologies for enhanced efficacy of DNA vaccines. Expert Rev Vaccines. 2012;11(2):189–209. doi:https://doi.org/10.1586/erv.11.188.
- Niwa R, Shoji-Hosaka E, Sakurada M, Shinkawa T, Uchida K, Nakamura K, Matsushima K, Ueda R, Hanai N, Shitara K. Defucosylated chimeric anti-cc chemokine receptor 4 IgG1 with enhanced antibody-dependent cellular cytotoxicity shows potent therapeutic activity to T-cell leukemia and lymphoma. Cancer Res. 2004;64(6):2127–33. doi:https://doi.org/10.1158/0008-5472.CAN-03-2068.
- Imai T, Nagira M, Takagi S, Kakizaki M, Nishimura M, Wang J, Gray PW, Matsushima K, Yoshie O. Selective recruitment of CCR4-bearing Th2 cells toward antigen-presenting cells by the CC chemokines thymus and activation-regulated chemokine and macrophage-derived chemokine. Int Immunol. 1999;11(1):81–88. doi:https://doi.org/10.1093/intimm/11.1.81.
- Zhang P, Dairaghi DJ, Jaen JC, Powers JP. Recent advances in the discovery and development of CCR1 antagonists. Ann Rep Med Chem. 2013;48:133–47.
- Hutchings CJ, Cseke G, Osborne G, Woolard J, Zhukov A, Koglin M, Jazayeri A, Pandya-Pathak J, Langmead CJ, Hill SJ, et al. Monoclonal anti-β1-adrenergic receptor antibodies activate G protein signaling in the absence of β-arrestin recruitment. MABS. 2014;6(1):246–61. doi:https://doi.org/10.4161/mabs.27226.
- Hennen S, Kodra JT, Soroka VX, Krogh BO, Wu X, Kaastrup P, Ørskov C, Rønn SG, Schluckebier G, Barbateskovic S, et al. Structural insight into antibody-mediated antagonism of the glucagon-like peptide-1 receptor. Sci Rep. 2016;6(1):26236. doi:https://doi.org/10.1038/srep26236.
- Procopiou PA, Barrett JW, Barton NP, Begg M, Clapham D, Copley RC, Ford AJ, Graves RH, Hall DA, Hancock AP, et al. Synthesis and structure–activity relationships of indazole arylsulfonamides as allosteric CC-chemokine receptor 4 (CCR4) antagonists. J Med Chem. 2013;56(5):1946–60. doi:https://doi.org/10.1021/jm301572h.
- Xu Y, Roach W, Sun T, Jain T, Prinz B, Yu T-Y, Torrey J, Thomas J, Bobrowicz P, Vásquez M, et al. Addressing polyspecificity of antibodies selected from an in vitro yeast presentation system: a FACS-based, high-throughput selection and analytical tool. Protein Engineering Design and Selection. 2013;26(10):663–70. doi:https://doi.org/10.1093/protein/gzt047.
- Yang Z, Wan Y, Tao P, Qiang M, Dong X, Lin C-W, Yang G, Zheng T, Lerner RA. A cell–cell interaction format for selection of high-affinity antibodies to membrane proteins. PNAS. 2019;116(30):14971–78. doi:https://doi.org/10.1073/pnas.1908571116.
- Ishchenko A, Wacker D, Kapoor M, Zhang A, Han GW, Basu S, Patel N, Messerschmidt M, Weierstall U, Liu W, et al. Structural insights into the extracellular recognition of the human serotonin 2B receptor by an antibody. PNAS. 2017;114(31):8223–28. doi:https://doi.org/10.1073/pnas.1700891114.
- Douthwaite JA, Sridharan S, Huntington C, Hammersley J, Marwood R, Hakulinen JK, Ek M, Sjögren T, Rider D, Privezentzev C, et al. Affinity maturation of a novel antagonistic human monoclonal antibody with a long VH CDR3 targeting the Class A GPCR formyl-peptide receptor 1. MABS. 2015;7(1):152–66. doi:https://doi.org/10.4161/19420862.2014.985158.
- Ma Y, Ding Y, Song X, Ma X, Li X, Zhang N, Song Y, Sun Y, Shen Y, Zhong W, et al. Structure-guided discovery of a single-domain antibody agonist against human apelin receptor. Sci Adv. 2020;6(3):eaax7379. doi:https://doi.org/10.1126/sciadv.aax7379.